Revelation Biosciences, Inc.
REVB
$2.72
$0.145.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.49% | -2.67% | -1.88% | 10.20% | 23.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.92% | -8.62% | -7.87% | 13.22% | 59.59% |
| Operating Income | 14.92% | 8.62% | 7.87% | -13.22% | -59.59% |
| Income Before Tax | 46.78% | -60.79% | -12,400.83% | -1,873.22% | -781.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.78% | -60.79% | -12,400.83% | -1,873.22% | -781.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.78% | -60.79% | -12,400.83% | -1,873.22% | -781.72% |
| EBIT | 14.92% | 8.62% | 7.87% | -13.22% | -59.59% |
| EBITDA | 14.99% | 8.69% | 7.93% | -13.24% | -59.82% |
| EPS Basic | 81.22% | -160.54% | -- | -- | -- |
| Normalized Basic EPS | 82.31% | -160.54% | -- | -- | -- |
| EPS Diluted | 81.17% | -160.69% | -- | -- | -- |
| Normalized Diluted EPS | 82.31% | -160.54% | -- | -- | -- |
| Average Basic Shares Outstanding | 2,184.86% | 2,231.28% | -- | -- | -- |
| Average Diluted Shares Outstanding | 2,184.86% | 2,231.28% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |